IMVAMUNE (MVA-BN)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smallpox
Conditions
Smallpox
Trial Timeline
Apr 1, 2003 → Dec 1, 2005
NCT ID
NCT00189956About IMVAMUNE (MVA-BN)
IMVAMUNE (MVA-BN) is a phase 2 stage product being developed by Bavarian Nordic for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT00189956. Target conditions include Smallpox.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00316589 | Phase 2 | Completed |
| NCT00189904 | Phase 1/2 | Completed |
| NCT00189917 | Phase 1 | Completed |
| NCT00189956 | Phase 2 | Completed |
Competing Products
20 competing products in Smallpox